Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
DURHAM, N.C. - Bioventus Inc. (NASDAQ:BVS) shares surged 28% in premarket trading on Tuesday after the medical device company reported better-than-expected fourth quarter results and provided an optimistic forecast for 2025.
The company, which specializes in innovations for active healing, posted Q4 revenue of $153.6 million, surpassing analyst estimates of $145.2 million. Revenue grew 13.5% YoY, driven by double-digit growth in Pain Treatments and Surgical Solutions segments.
For the full year 2025, Bioventus projects revenue between $560 million to $570 million, ahead of the $554.8 million consensus estimate. The company also expects adjusted earnings per share of $0.64 to $0.68, topping analyst expectations of $0.55.
"Our Bioventus team delivered strong results in the fourth quarter to conclude a very successful and transformational year for our company," said Rob Claypoole, Bioventus President and Chief Executive Officer. "Looking forward, we believe we are well positioned to build on this positive momentum, driving above-market revenue growth with a multitude of diverse growth drivers, while enhancing profitability and accelerating cash flow to create significant shareholder value."
The company reported Q4 adjusted EBITDA of $28.3 million, up 28.3% from $22.0 million in the prior year period. Adjusted gross margin expanded 230 basis points to 73.7%.
Bioventus said it generated $19.3 million in cash from operations in Q4, an 86.3% increase from the previous year. The company also reduced its long-term debt by $48.3 million during the quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.